Europe · Markets & Finance · Finanz und Wirtschaft

Neurosterix schliesst Phase-1-Studie zu Schizophrenie ab

Published by Finanz und Wirtschaft · Switzerland 19 h ago

Das Spin-out des Biotech-Unternehmens Addex will den Wirkstoff Ntx-253 nun in einer Phase-2-Studie an Schizophrenie-Patienten testen.

Read the full article on Finanz und Wirtschaft Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fuw.ch)

Also worth reading

Amazon job cuts hit hundreds as tech giant denies AI link

Financial Times

Oil prices jump on tanker attack and slowing flows through Strait of Hormuz

Slash your retirement tax bill by tens of thousands: Far too many are paying a hefty price for spending their pension pots unwisely. Try these four hacks that won't cost you a single penny

The Yen is capitalising on the Euro’s weakness

Reuters Markets

'Dangerous' for BoE to rely on high bond yields to control inflation, MPC's Greene says

Reuters Sustainability

European shares, euro fall as energy shock, fiscal worries bite